Alexandra Sowa's new book The Ozempic Revolution is intended to be the "first comprehensive user guide" to GLP-1 drugs like ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
With with GLP-1 drugs, gastrointestinal issues, such as nausea, vomiting, constipation, and gastroesophageal reflux disease, ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
Novo Nordisk's GLP-1 agonist Ozempic has become the first drug in the class to be approved by the FDA to reduce the risk of ...
GLP1-based obesity medicines, such as Ozempic and Wegovy, have surged in popularity and become the subject of intense public ...
In all, researchers found that people taking GLP-1 medications had lower risks for 42 health outcomes, including liver ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
“GLP1s represent a new landscape ... dementia-protecting benefit when they found participants taking GLP-1 drugs had a decreased risk of neurocognitive conditions such as dementia and Alzheimer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback